Gd-BOPTA/Dimeg
Gd-BOPTA/Dimeg Brand names, Gd-BOPTA/Dimeg Analogs
Gd-BOPTA/Dimeg Brand Names Mixture
- No information avaliable
Gd-BOPTA/Dimeg Chemical_Formula
C22H28GdN3O11
Gd-BOPTA/Dimeg RX_link
No information avaliable
Gd-BOPTA/Dimeg fda sheet
Gd-BOPTA/Dimeg msds (material safety sheet)
Gd-BOPTA/Dimeg Synthesis Reference
No information avaliable
Gd-BOPTA/Dimeg Molecular Weight
667.7 g/mol
Gd-BOPTA/Dimeg Melting Point
No information avaliable
Gd-BOPTA/Dimeg H2O Solubility
No information avaliable
Gd-BOPTA/Dimeg State
No information avaliable
Gd-BOPTA/Dimeg LogP
No information avaliable
Gd-BOPTA/Dimeg Dosage Forms
Liquid; Solution
Gd-BOPTA/Dimeg Indication
For magnetic resonance imaging (MRI) of the central nervous system in adults to visualize lesions with abnormal blood brain barrier or abnormal vascularity of the brain, spine, and associated tissues.
Gd-BOPTA/Dimeg Pharmacology
Gadobenate dimeglumine shares the pharmacokinetic properties of the ECF contrast agent gadopentetate dimeglumine; however, gadobenate differs in that is also selectively taken-up by hepatocytes and excreted via the bile (up to 5% of dose). The elimination half-life of gadobenate dimeglumine is approximately 1 hour. It is not metabolized.
Gd-BOPTA/Dimeg Absorption
No information avaliable
Gd-BOPTA/Dimeg side effects and Toxicity
No information avaliable
Gd-BOPTA/Dimeg Patient Information
No information avaliable
Gd-BOPTA/Dimeg Organisms Affected
Humans and other mammals
